Nicotine PK of M1 Platform Compared to Cigarettes and Inhalator

  • Research type

    Research Study

  • Full title

    An Open-Label, Randomised, Controlled, Crossover Study to Assess Nicotine Pharmacokinetics of the M1 Platform Compared to Combustible Cigarettes and the Nicorette Inhalator

  • IRAS ID

    304673

  • Contact name

    Samuel Israel

  • Contact email

    samuel.israel@fortrea.com

  • Sponsor organisation

    Juul Labs, Inc.

  • Eudract number

    2021-005476-19

  • Duration of Study in the UK

    0 years, 2 months, 5 days

  • Research summary

    This study is an Open label, randomised, controlled, crossover study evaluating nicotine levels (pharmacokinetics) of the M1 Platform electronic nicotine delivery system (D1+ device with a 5% nicotine and Virginia Tobacco Flavour J2 JUULpod, D1 + Device with 3% nicotine and Menthol Flavour J2 JUULpod and D1+ Device with 5% nicotine and Menthol Flavour J2 JUULpod), a combustible cigarette, and the Nicorette Inhalator.\n\nParticipants who successfully complete the screening assessments will use one of the study products at each of 5 Study Visits during controlled puffing sessions (each controlled puff sequence session includes 10 puffs of 3 seconds each, spaced 30 seconds apart), according to a randomisation schedule. Each Study Visit will involve a check-in on Day-1, 5 controlled puffing sequence sessions spaced 60 minutes apart on Days 1, 2, 3, 4, and 5 and a check-out later on Day 1. Participants will receive a follow-up telephone call approximately 7 days after their last Study Visit.\n\nThe study products are as follows:\nA\tM1 Platform (D1+ Device with a 5% Nicotine and Virginia Tobacco Flavour J2 JUULpod)\nB\tM1 Platform (D1+ Device with 3% Nicotine and Menthol Flavour J2 JUULpod)\nC\tM1 Platform (D1+ Device with 5% Nicotine and Menthol Flavour J2 JUULpod)\nD\tNicorette 15 mg Inhalator\nE\tParticipants’ usual brand combustible cigarette\n\n\nThe total study duration is anticipated to be no more than 7 weeks per study participant.\n\nThe study will be conducted at a single research centre (Labcorp Clinical Research Unit Ltd, Leeds). Male or female current smokers who have either tried or are occasional users of e cigarettes will be enrolled to obtain 30 completers of all 5 Study Visits.\n

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    21/LO/0770

  • Date of REC Opinion

    20 Dec 2021

  • REC opinion

    Further Information Favourable Opinion